List view / Grid view

News

Bristol-Myers Squibb Foundation awards nine grants totaling more than $3.5 million to support care for high-risk patients with hepatitis B and C in China and India

4 December 2014 | By Bristol-Myers Squibb Foundation

The Bristol-Myers Squibb Foundation announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations...

Bristol-Myers Squibb Foundation marks World AIDS Day by awarding $1.47 million in new grants to strengthen HIV-related services in five sub-Saharan countries

2 December 2014 | By The Bristol-Myers Squibb Foundation

The Bristol-Myers Squibb Foundation marked World AIDS Day by announcing 12 new grants totaling $1.47 million that focus on strengthening community-based services in sub-Saharan Africa for adolescents and the elderly who are living with HIV and for HIV patients with comorbid female cancers or tuberculosis...

Application submitted to the EMA to expand the therapeutic indication for IMBRUVICA® (ibrutinib) to include treatment of Waldenström’s macroglobulinemia

1 December 2014 | By Janssen-Cilag International

Janssen-Cilag International NV (Janssen) announced today the submission of a Type II variation application to the European Medicines Agency (EMA) to vary the marketing authorisation for IMBRUVICA® (ibrutinib), to include a new therapeutic indication, the treatment of adult patients with Waldenström’s macroglobulinemia (WM). If approved, this latest regulatory submission will…

Arthurian brings leading US medtech firm to Wales

1 December 2014 | By Arthurian Life Sciences

Arthurian Life Sciences, the specialist fund management company led by Professor Sir Chris Evans, announced it has formed a partnership with one of the leading medtech firms in the US, Interrad Medical Inc...